Medpace Holdings, Inc. $MEDP Position Raised by Campbell Newman Asset Management Inc.

Key Points

• Campbell Newman Asset Management Inc. increased its stake in Medpace Holdings by 7.1%, owning 9,348 shares valued at approximately $2.93 million as of its latest SEC filing.
• Multiple analysts have updated their ratings for Medpace, with Zacks Research downgrading it from "strong-buy" to "hold," while Mizuho raised its price target significantly to $510.00.
• Insider trading shows some notable sales, with CEO August J. Troendle selling 36,196 shares for over $17.2 million, resulting in a 3.76% decrease in their ownership.

Campbell Newman Asset Management Inc. grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,348 shares of the company's stock after acquiring an additional 622 shares during the quarter. Campbell Newman Asset Management Inc.'s holdings in Medpace were worth $2,934,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group boosted its position in shares of Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after buying an additional 71 shares during the period. Whittier Trust Co. grew its holdings in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Medpace in the 1st quarter valued at approximately $60,000. Finally, Assetmark Inc. raised its stake in Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on MEDP shares. Zacks Research cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 22nd. TD Cowen restated a "sell" rating and set a $366.00 price target (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Mizuho boosted their target price on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $422.27.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the transaction, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president owned 57,500 shares in the company, valued at $27,600,000. This represents a 14.81% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

Medpace Stock Performance

Medpace stock opened at $500.76 on Tuesday. The firm has a market cap of $14.07 billion, a price-to-earnings ratio of 37.23, a price-to-earnings-growth ratio of 3.13 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $506.55. The firm's 50 day moving average price is $468.67 and its two-hundred day moving average price is $362.54.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. During the same period in the previous year, the firm posted $2.75 EPS. The company's quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.